Developing a Functional Cure for HIV Disease: Clinical Specimen Collection From HIV Positive Individuals

Inclusion Criteria: * Male or female aged between ≥18 and ≤60 years * Documented HIV infection for at least 3 years prior to study entry * Stable on HIV antiretroviral regimen with viral suppression to \<50c/mL plasma for \>2 years * Agrees not to change antiretroviral regimen (unless medically indicated) during the study period * CD4+ T cell count \>500 cell per millimeter cubed (cells/mm3) at last measurement within 6 months of study participation * CD4+ T cell nadir of \>350 cells/mm3 * HIV plasma viral load \<50 copies of viral RNA per milliliter (mL) for \>2 years * Participants who had intermittent, isolated episodes of detectable low-level viremia (\<500c/mL; blips) will remain eligible. * Have not received cytoreduction therapy within 3 months of study entry * Do not have prior events of hemorrhagic cystitis * Is not being treated or does not have bacteremia within the past 6 months * Does not have signs or symptoms of acute infectious disease * Adequate venous access and no other contraindications for leukapheresis * Hematocrit is \>33% or hemoglobin is ≥13g/dL (males) and ≥12g/dL (females) at last measurement within 7 days prior to study enrollment; test also required within 3 days prior to leukapheresis * Weighs more than 75 lbs * Not pregnant at time of enrollment * Ability to understand the study and must be willing to comply with study-required procedures and visits, including only changing antiretroviral regimen when indicated by the study doctor during the study period * Written informed consent signed and dated by study participant Exclusion Criteria: * Acute or chronic hepatitis B or hepatitis C infection with detectable viremia * Any viral hepatitis or liver disease (e.g. cirrhosis) * Active or recent (prior 6 months) AIDS defining complication * Any experimental HIV medications within the past 12 weeks * Cancer or malignancy that has not been in remission for at least 5 years with the exception of successfully treated basal cell carcinoma of the skin * Current diagnosis of NYHA grade 3 or 4 congestive heart failure or uncontrolled angina or arrhythmias * Any clinically significant renal, hepatic, and pulmonary disease * Inadequate venous access or contraindicated for leukapheresis * Significant laboratory values and/or a chronic medical condition that, in the opinion of the Principal Investigator, could impact trial participation * Receiving another investigational drug or device within 30 days of study entry * Previously received any gene transfer therapy * History or any features on physical examination indicative of a bleeding diathesis * Use of chronic corticosteroids, hydroxyurea, or immunomodulating agents (e.g. interleukin-2, interferon-alpha or gamma, granulocyte colony stimulating factors, etc.) within 30 days prior to screening (NOTE: Use of inhaled or topical steroids is not exclusionary) * Breast-feeding or pregnant * Use of aspirin, dipyridamole, warfarin or any other medication that is likely to affect platelet function or other aspects of blood coagulation during the 2-week period prior to leukapheresis * Active drug or alcohol use or dependence that, in the opinion of the Investigator, would interfere with adherence to study requirements * Serious illness requiring systemic treatment and/or hospitalization within 30 days prior to study entry * Recent vaccination or intercurrent illness within 5 weeks prior to T cell infusion (NOTE: It is recommended that participants should have completed their routine vaccinations, e.g. hepatitis A or B, pneumococcus, influenza and tetanus diphtheria booster, at least 30 days prior to screening for the study) * Asplenia: any conditions resulting in the absence of a functional spleen * History of hereditary angioedema, acquired angioedema or idiopathic angioedema